Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant long-course chemoradiotherapy plus camrelizumab for locally advanced or low rectal cancer
ChiCTR2300079265Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in rectal cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: pathological complete response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2300079265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079265.